Clinical and biological heterogeneities in triple-negative breast cancer reveals a non-negligible role of HER2-low

HER2-low could be found in some patients with triple-negative breast cancer (TNBC). However, its potential impacts on clinical features and tumor biological characteristics in TNBC remain unclear. We enrolled 251 consecutive TNBC patients retrospectively, including 157 HER2-low (HER2 ) and 94 HER2-n...

Full description

Saved in:
Bibliographic Details
Published in:Breast cancer research : BCR 2023-03, Vol.25 (1), p.34-34, Article 34
Main Authors: Hu, Xi E, Yang, Ping, Chen, Songhao, Wei, Gang, Yuan, Lijuan, Yang, Zhenyu, Gong, Li, He, Li, Yang, Lin, Peng, Shujia, Dong, Yanming, He, Xianli, Bao, Guoqiang
Format: Article
Language:English
Subjects:
Bar codes
Breast cancer
Breast Neoplasms
Cancer therapies
CD8 antigen
Clinical outcomes
Effector cells
ErbB-2 protein
Female
Gene expression
HER2-low
Heterogeneity
Humans
Immunofluorescence
Immunotherapy
Ki-67 Antigen
Lymph nodes
Lymphocytes T
Macrophages
Medical prognosis
Medical records
Medical research
Medicine, Experimental
Microenvironments
Phenotypes
Prognosis
Retrospective Studies
RNA sequencing
Single-cell RNA sequencing
T cells
Triple Negative Breast Neoplasms - drug therapy
Triple Negative Breast Neoplasms - therapy
Triple-negative breast cancer
Tumor microenvironment
Tumor Microenvironment - genetics
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:HER2-low could be found in some patients with triple-negative breast cancer (TNBC). However, its potential impacts on clinical features and tumor biological characteristics in TNBC remain unclear. We enrolled 251 consecutive TNBC patients retrospectively, including 157 HER2-low (HER2 ) and 94 HER2-negtive (HER2 ) patients to investigate the clinical and prognostic features. Then, we performed single-cell RNA sequencing (scRNA-seq) with another seven TNBC samples (HER2 vs. HER2 , 4 vs. 3) prospectively to further explore the differences of tumor biological properties between the two TNBC phenotypes. The underlying molecular distinctions were also explored and then verified in the additional TNBC samples. Compared with HER2 TNBC, HER2 TNBC patients exhibited malignant clinical features with larger tumor size (P = 0.04), more lymph nodes involvement (P = 0.02), higher histological grade of lesions (P 
ISSN:1465-542X
1465-5411
1465-542X
DOI:10.1186/s13058-023-01639-y